| Ytd | 15.71% | |
| 1y | 8.08% |
| Open | 3.64 | Prev Close | 3.56 | Low | 3.57 | High | 3.69 | Mkt Cap | 121.12M |
| Vol | 254.45K | Avg Vol | 197.27K | EPS | -0.31 | P/E | -11.48 | Forward P/E | -7.17 |
| Beta | 0.59 | Short Ratio | 3.03 | Inst. Own | 17.46% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-10 | 50-d Avg | 2.85 | 200-d Avg | 3.29 | 1yr Est | 8.50 |
ANIX News
HTLD, YEXT, ANIX, WVE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 20
Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market s
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology c
Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform C
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology c
Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limitin
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co
Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints w
Anixa advances cancer vaccines and CAR-T therapies, supported by positive early data, a planned phas
Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations fro
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analys
Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the preven
Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the preven
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co
Multiple patients have survived substantially beyond expected median survival, including onepatient
SAN JOSE, Calif., May 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NA
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co
Expands global intellectual property coverage in markets with greater late-stage breast cancerdiagno
Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trialSAN JOSE, Cali
Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trial SAN JOSE, Cal
AVAX Technologies (OTCMKTS:AVXT - Get Free Report) and Anixa Biosciences (NASDAQ: ANIX - Get Free Re
Breast cancer vaccine met primary endpoints and generated protocol-defined immuneresponses in 74% of
Breast cancer vaccine met primary endpoints and generated protocol-defined immune responses in 74% o
SAN JOSE, Calif., April 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (
Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, a
Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, a
Dr. Robert Wenham of Moffitt Cancer Center and principal investigator of the trial to present lira-c
Dr. Robert Wenham of Moffitt Cancer Center and principal investigator of the trial to present lira-c
SAN JOSE, Calif., March 12, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company")
Notice of Allowance marks first Korean patent covering Anixa's breast cancer vaccine platform Expand
Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation, as well as Fi
On Tuesday, 647 companies set new 52-week lows.
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Wednesday